Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 7/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977066 | 0.91 | ENPP2 (0.34) | CTSSCTSKSLC6A9UTS2RENPP2 | |
| SCHEMBL975170 | 0.85 | SLC6A9 (0.38) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL974850 | 0.84 | POLB (0.38) | SLC6A9UTS2RENPP2CACNA2D1CACNA1B | |
| SCHEMBL977174 | 0.84 | SCN9A (0.35) | CTSSCTSKSLC6A9CNR1SCN9A | |
| SCHEMBL976386 | 0.81 | CTSD (0.39) | UTS2RCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL976518 | 0.81 | CTSD (0.39) | UTS2RCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL974739 | 0.80 | F2 (0.34) | SLC6A9 | |
| SCHEMBL974838 | 0.80 | F2 (0.34) | SLC6A9 | |
| SCHEMBL977199 | 0.80 | KDM4E (0.36) | SLC6A9P2RX3UTS2RSCN9AP2RX7 | |
| SCHEMBL976966 | 0.78 | F2 (0.35) | SLC6A9UTS2RCNR1CACNA2D1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445478-B2 | Azetidine derivatives, their preparation and their application in therapy | SANOFI (FR) | 2013-05-21 | — | — | US | claimed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | CTSS 2065/4885CTSK 2060/4885SLC6A9 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.